Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 329

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 329
---
15 | % |
| Effective tax rate                                 |     |      |  -0.02 | % |     |      |   0.00 | % |

The Company made an acquisition in 2023. The transaction was complex and when preparing the tax provision for the year ended December 31, 2023, the Company made the assumption that the acquisition was taxable asset acquisition for US federal income tax purposes when preparing its initial estimates. The Company booked a deferred tax asset for the intangible tax basis assumed to be acquired in a deemed asset acquisition of $ 16.2 million which would have been amortized over the next 15 years. After further analysis of the complex transaction, it was determined that the acquisition met the criteria of a tax free reorganization under Section 368(a) and was not a taxable asset acquisition. Therefore, the Company filed its 2023 income tax returns to correctly reflect the acquisition as a tax free reorganization and the temporary book-to-tax difference for intangible tax basis estimate was reclassified a permanent adjustment of $ 16.1 million (net of carryover tax basis). This resulted in a - 18.89% impact to the Company’s effective tax rate for the tax year ended December 31, 2024.

<div align='center'>F-8 7</div>

TUHURA BIOSCIENCES, INC AND SUBSIDIARIES Notes to the consolidated financial statements For the years ended December 31, 2024, and 2023

The components for the Company’s deferred tax assets and liabilities as of December 31, 2024 and 2023, were as follows:

| Deferred tax assets:                      |     | 2024 |             |   |     | 2023 |             |   |
|:------------------------------------------|:----|:-----|------------:|:--|:----|:-----|------------:|:--|
| Net operating loss carryforwards          |     | $    |  25,098,126 |   |     | $    |  11,143,664 |   |
| Stock compensation expense                |     |      |   2,467,541 |   |     |      |     589,118 |   |
| Accrued payroll                           |     |      |     294,420 |   |     |      |     358,732 |   |
| Section 174 R&D                           |     |      |   6,172,